PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
29344879-5	2018	In the aspirin group, the changes from baseline to end point in the IIEF-EF, SEP-2, and SEP-3 scores were 7.2, 36.6, and 46.6%, respectively.	Aspirin	7-14	septin 3	Homo sapiens	88-93
27160157-7	2017	Response to SEP3, PAIRS and EHS was significantly higher in the tadalafil de-escalation group than in the tadalafil 5 mg group (p < 0.05).	Tadalafil	64-73	septin 3	Homo sapiens	12-16
25813656-8	2015	The ability for successful sexual intercourse (SEP3) significantly improved with tadalafil OaD vs placebo only during DBT.	Tadalafil	81-90	septin 3	Homo sapiens	47-51
27034723-5	2016	In the treatment of diabetic ED, a traditionally difficult-to-treat population, 100 mg mirodenafil has been reported to offer favorable efficacy (with improvements in the IIEF-EF scores, and positive responses to the SEP2 and the SEP3: 9.3 points, 36.1% and 61.8%, respectively) and tolerability (mild adverse effects of less than 19.6%), which are comparable with results from clinical studies on other PDE5Is.	mirodenafil	87-98	septin 3	Homo sapiens	230-234
26083929-8	2015	Moreover, a temperature increase was observed to induce dissociation of SEPT3-GC dimers into monomers just preceding their reassembling into amyloid aggregates, as revealed by the Thioflavin-T fluorescence assays.	thioflavin T	180-192	septin 3	Homo sapiens	72-77
24589460-7	2014	Among the co-primary efficacy end points indicating that avanafil 100 mg was more effective than a placebo were successful vaginal penetration (SEP2) (the odds ratio (OR) =5.06, 95% confidence interval (CI) =3.29-7.78, P< 0.00001) and successful intercourse (SEP3) (OR = 3.99, 95% CI = 2.80-5.67, P< 0.00001).	avanafil	57-65	septin 3	Homo sapiens	262-266
25370206-9	2015	The SEP2 (penetration), SEP3 (successful intercourse), and IIEF-EF domain scores were improved in both tadalafil and sildenafil treatment groups.	Tadalafil	103-112	septin 3	Homo sapiens	24-28
25370206-9	2015	The SEP2 (penetration), SEP3 (successful intercourse), and IIEF-EF domain scores were improved in both tadalafil and sildenafil treatment groups.	Sildenafil Citrate	117-127	septin 3	Homo sapiens	24-28
24701971-6	2014	The pairwise meta-analysis suggested that avanafil was more effective than placebo in improving IIEF-EF (mean difference [MD]: 4.47; 95% confidence interval [CI]: 3.51 to 5.43), SEP-2 (MD: 17.41; 95% CI: 14.03 to 20.79), and SEP-3 (MD: 20.01; 95% CI: 22.98 to 37.22), with an evident dose-response relationship.	avanafil	42-50	septin 3	Homo sapiens	225-230
23757969-7	2013	After 3 months of daily tadalafil treatment at 10 mg, the IIEF-5 scores were significantly improved in the abnormal nocturnal erection group than in the non-nocturnal erection group (P < 0.05), and the rate of yes responses to SEP2 and SEP3 was remarkably higher in the former than in the latter (76.9% vs 41.7% and 65.4% vs 25.0%, P < 0.05).	Tadalafil	24-33	septin 3	Homo sapiens	239-243
23219537-8	2013	Following dosing with avanafil 36.4% (28 of 77) of sexual attempts (SEP3) at 15 minutes or less were successful vs 4.5% (2 of 44) for placebo (p <0.01).	avanafil	22-30	septin 3	Homo sapiens	68-72
23961850-10	2013	In patients with baseline HbA(1c) >= 7%, SEP 3 was achieved by 35% of patients on a vildagliptin-based combination and by 23% of those receiving comparator combinations.	Vildagliptin	87-99	septin 3	Homo sapiens	44-49
23163726-7	2013	This construct (SEPT3-GC), which includes the GTP-binding and C-terminal domains, purifies as a nucleotide-free monomer, allowing for its characterization in terms of GTP-binding and hydrolysis.	Guanosine Triphosphate	167-170	septin 3	Homo sapiens	16-21
22931760-6	2012	Losartan or tadalafil or losartan plus tadalafil significantly improved the mean IIEF-5 scores, the percentage of successful penetrations (SEP2), the successful intercourse completions (SEP3) and GAQ (P<0.05).	Losartan	0-8	septin 3	Homo sapiens	186-190
23163726-7	2013	This construct (SEPT3-GC), which includes the GTP-binding and C-terminal domains, purifies as a nucleotide-free monomer, allowing for its characterization in terms of GTP-binding and hydrolysis.	Guanosine Triphosphate	46-49	septin 3	Homo sapiens	16-21
22931760-6	2012	Losartan or tadalafil or losartan plus tadalafil significantly improved the mean IIEF-5 scores, the percentage of successful penetrations (SEP2), the successful intercourse completions (SEP3) and GAQ (P<0.05).	Tadalafil	12-21	septin 3	Homo sapiens	186-190
22931760-6	2012	Losartan or tadalafil or losartan plus tadalafil significantly improved the mean IIEF-5 scores, the percentage of successful penetrations (SEP2), the successful intercourse completions (SEP3) and GAQ (P<0.05).	Losartan	25-33	septin 3	Homo sapiens	186-190
22931760-6	2012	Losartan or tadalafil or losartan plus tadalafil significantly improved the mean IIEF-5 scores, the percentage of successful penetrations (SEP2), the successful intercourse completions (SEP3) and GAQ (P<0.05).	Tadalafil	39-48	septin 3	Homo sapiens	186-190
19473285-9	2009	RESULTS: Compared with placebo, tadalafil-treated subjects showed a significant improvement on efficacy measures (P < 0.001) including changes in the IIEF-EF, SEP-2 and SEP-3.	Tadalafil	32-41	septin 3	Homo sapiens	172-177
21243762-5	2010	RESULTS: Tadalafil treatment significantly improved IIEF-5 score, SEP2 and SEP3 of both groups of the patients (P < 0.01).	Tadalafil	9-18	septin 3	Homo sapiens	75-79
20626604-8	2010	Differences between the mirodenafil and placebo groups were significant in the SEP2 (82.0% vs. 55.2%, P = 0.0003), SEP3 (68.9% vs. 22.3%, P < 0.0001).	mirodenafil	24-35	septin 3	Homo sapiens	115-119
19377488-6	2009	The 10-mg and 20-mg tadalafil groups showed a mean success rate of 64.1% and 70.5% for sexual intercourse attempts (SEP3, successful intercourse), respectively, compared with 33.4% in the placebo group (P < 0.001), and 85.5% and 85.4% reported improved erections at end point GAQ, respectively, versus 43.5% in the placebo group (P < 0.001).	Tadalafil	20-29	septin 3	Homo sapiens	116-120
22857780-4	2012	RESULTS: Compared with placebo, least-squares mean change from baseline to study end in SEP 3, SEP 2, and International Index of Erectile Function erectile function domain score were significantly improved with both avanafil, 100 mg (P<=.002), and avanafil, 200 mg (P<.001).	avanafil	216-224	septin 3	Homo sapiens	88-93
21679304-11	2011	Least squares (LS) mean SEP3 overall success rates after 12 weeks of treatment were 9.5 (baseline) vs. 67.2 (week 12) and 12.4 (baseline) vs. 24.2 (week 12) in the vardenafil and placebo groups, respectively (P < 0.0001).	Vardenafil Dihydrochloride	164-174	septin 3	Homo sapiens	24-28
20649936-8	2010	The mirodenafil group also demonstrated significantly greater improvement in scores of IIEF Q3 and Q4, other four domains of IIEF, SEP2, SEP3, and LSC along with percentages of patients responding positively to GAQ compared with the placebo group.	mirodenafil	4-15	septin 3	Homo sapiens	137-141
20456213-8	2010	Vardenafil ODT therapy was statistically significantly superior to placebo for all primary (i.e. IIEF-EF, SEP2, SEP3) and secondary efficacy variables (p < 0.0001).	Vardenafil Dihydrochloride	0-14	septin 3	Homo sapiens	112-116
20233275-9	2010	Vardenafil ODT therapy was statistically significantly superior to placebo for all primary (IIEF-EF, SEP2, SEP3) and secondary efficacy measures (all P < 0.0001).	Vardenafil Dihydrochloride	0-14	septin 3	Homo sapiens	107-111
19732311-1	2009	INTRODUCTION: Vardenafil is reported to improve success rates in the maintenance of an erection sufficient for completion of intercourse (SEP-3) compared with placebo in erectile dysfunction (ED) patients who attempted intercourse from as early as 15 minutes after dosing.	Vardenafil Dihydrochloride	14-24	septin 3	Homo sapiens	138-143
19732311-11	2009	SEP-3 success rates in patients who inserted in each interval from 0-15 minutes (P = 0.0268), 15-30 minutes (P = 0.0094) through > 120 minutes were all higher in vardenafil-treated patients than those in placebo.	Vardenafil Dihydrochloride	165-175	septin 3	Homo sapiens	0-5
20027555-10	2009	CONCLUSION: The recommended maximum dose for tadalafil insignificantly improved the IIEF5, SEP2, SEP3, and GAQ scores in patients with erectile dysfunction who had not responded to sildenafil and vardenafil.	Tadalafil	45-54	septin 3	Homo sapiens	97-101
18682779-12	2008	CONCLUSION: Vardenafil 20 mg had a high first-dose success rate for both SEP2 (81%) and SEP3 (70%); this was maintained through to the study end point (85% for SEP2 and 78% for SEP3).	Vardenafil Dihydrochloride	12-22	septin 3	Homo sapiens	88-92
18640769-11	2008	On-demand vardenafil treatment resulted in significantly greater IIEF-EF scores and better SEP3 response rates than placebo over the entire treatment period.	Vardenafil Dihydrochloride	10-20	septin 3	Homo sapiens	91-95
18682779-12	2008	CONCLUSION: Vardenafil 20 mg had a high first-dose success rate for both SEP2 (81%) and SEP3 (70%); this was maintained through to the study end point (85% for SEP2 and 78% for SEP3).	Vardenafil Dihydrochloride	12-22	septin 3	Homo sapiens	177-181
17498108-10	2007	Moreover, the average per patient intercourse completion (SEP3) success rate was significantly higher in the vardenafil group compared with placebo (69% vs. 23%; P < 0.0001).	Vardenafil Dihydrochloride	109-119	septin 3	Homo sapiens	58-62
18373526-10	2008	During the 12-week treatment period, the least squares (LS) adjusted mean success rates in patients on vardenafil vs. placebo were: SEP2, 79.09% vs. 51.92%; and SEP3, 66.69% vs. 33.83% (P < 0.001).	Vardenafil Dihydrochloride	103-113	septin 3	Homo sapiens	161-165
18595542-10	2008	In 69% of the young disabled males, tadalafil-mediated erection was sufficient to perform a satisfactory intercourse (SEP3, p = 0.001).	Tadalafil	36-45	septin 3	Homo sapiens	118-122
18304286-9	2008	At least 56% of attempts at sexual intercourse were successfully completed (SEP3) at all time intervals up to 36 hours after tadalafil administration.	Tadalafil	125-134	septin 3	Homo sapiens	76-80
17727740-7	2007	Similarly, success rates for the ability to maintain erections (SEP3) improved 38.0% (95% CI: 29.5%, 46.6%) compared to placebo, with individual trial values ranging from 41.7% to 88.2% for vardenafil and 20.5% to 51.4% for placebo.	Vardenafil Dihydrochloride	190-200	septin 3	Homo sapiens	64-68
17727740-8	2007	Vardenafil was equally efficacious in improving IIEF-EF, SEP2, and SEP3 in those with and without self-reported HTN.	Vardenafil Dihydrochloride	0-10	septin 3	Homo sapiens	67-71
17687944-9	2007	RESULTS: Tadalafil significantly improved ED (p < 0.001) for 7.40 points of the IIEF score, i.e. for 58% and 60% towards SEP2 and SEP3 questionnaire, respectively.	Tadalafil	9-18	septin 3	Homo sapiens	133-137
18385912-8	2008	Vardenafil was associated with significant improvements from baseline in least squares (LS) mean success rates for SEP-2 (vardenafil 82.2 vs. placebo 43.6; P<0.001) and SEP-3 (vardenafil 66.1 vs. placebo 24.0; P<0.001).	Vardenafil Dihydrochloride	0-10	septin 3	Homo sapiens	172-177
17564677-7	2007	When over-expressed in HEK293 cells, Sept3 forms filamentous structures that are dependent on the presence of its GTP- and phosphoinositide-binding domains.	Guanosine Triphosphate	114-117	septin 3	Homo sapiens	37-42
17564677-7	2007	When over-expressed in HEK293 cells, Sept3 forms filamentous structures that are dependent on the presence of its GTP- and phosphoinositide-binding domains.	Phosphatidylinositols	123-139	septin 3	Homo sapiens	37-42
16942533-8	2006	Sexual intercourse was successfully completed (SEP3) in 76.3%, 80.1%, and 74.3% of subjects receiving 5, 10, and 20 mg vardenafil compared with 25.9%, 17.9%, and 19.2% at baseline, respectively.	Vardenafil Dihydrochloride	119-129	septin 3	Homo sapiens	47-51
17087800-5	2007	RESULTS: Patients with severe ED in the Japanese study experienced numerically greater increases (improvements) when taking tadalafil 20 mg compared with 10 mg in the IIEF-EF domain (14.3 vs. 12.4; P = 0.355), SEP2 (60% vs. 57%; P = 0.781), and SEP3 (61% vs. 49%, P = 0.196).	Tadalafil	124-133	septin 3	Homo sapiens	245-249
17087800-6	2007	When sufficiently powered, these observations reached statistical significance in the three PCTs: patients with severe ED experienced greater increases when taking tadalafil 20 mg compared with 10 mg in the IIEF-EF domain (13.6 vs. 10.4; P = 0.014) and SEP3 (56% vs. 43%, P = 0.019).	Tadalafil	164-173	septin 3	Homo sapiens	253-257
17100937-12	2006	Patients also had a higher percentage of positive responses for vardenafil for SEP2, SEP3, GAQ, and 12 of 19 questions on the TSS.	Vardenafil Dihydrochloride	64-74	septin 3	Homo sapiens	85-89
17378845-10	2007	There were significant benefits with vardenafil in all other variables (IIEF-EF scores and positive response rates to SEP-2 and SEP-3).	Vardenafil Dihydrochloride	37-47	septin 3	Homo sapiens	128-133
17233779-11	2007	The time between sildenafil ingestion and intercourse attempt (0-0.5 to >10 hours) had no significant effect on responses to SEP2, but decreased responses to SEP3 from a maximum of 92.8% at 1.5-2 hours to 81.6% at more than 10 hours (P = 0.003).	Sildenafil Citrate	17-27	septin 3	Homo sapiens	161-165
16212141-8	2005	During the double-blind phase, the reliability of penetration and maintenance rates for patients successful during the challenge phase were significantly greater with vardenafil compared with placebo (83.4% vs 55.8% [SEP2] and 76.6% vs 42.1% [SEP3], respectively).	Vardenafil Dihydrochloride	167-177	septin 3	Homo sapiens	243-247
16766116-6	2006	RESULTS: For patients who took placebo, tadalafil 5mg, and tadalafil 10mg, changes from baseline to endpoint were, respectively, 0.9, 9.7, and 9.4 for IIEF EF; 11.2, 36.5, and 39.4 for SEP2; and 13.2, 45.5, and 50.1 for SEP3.	Tadalafil	59-68	septin 3	Homo sapiens	220-224
16834650-9	2006	In patients receiving tadalafil 10 mg and 20 mg, the mean per-patient success rate for intercourse attempts (SEP3) was 62% and 70%, respectively, compared with 32% for the placebo group (P < 0.001).	Tadalafil	22-31	septin 3	Homo sapiens	109-113
16681476-7	2006	The mean per-patient percentage "yes" response on SEP question 3 (SEP3, successful intercourse) was 33 +/- 4% at baseline, 74 +/- 4% after 1 month, and 78 +/- 4% after 6 months of tadalafil treatment.	Tadalafil	180-189	septin 3	Homo sapiens	50-64
16681476-9	2006	In a subgroup of patients who took tadalafil > or =3 times per week (N = 24), the SEP3 score was 87 +/- 4% after 1 month and 93 +/- 3% after 6 months of treatment, and the IIEF EF domain score was 27.3 +/- 0.9 after 3 months and 28.5 +/- 0.4 after 6 months.	Tadalafil	35-44	septin 3	Homo sapiens	85-89
16681476-11	2006	CONCLUSIONS: Tadalafil treatment significantly improved SEP3 and IIEF EF domain scores.	Tadalafil	13-22	septin 3	Homo sapiens	56-60
16422806-8	2005	RESULTS: Compared with placebo at LOCF, vardenafil significantly increased least square (LS) mean scores in: (i) overall per-treated male SEP3 success rate, IIEF-EF, and EQS; and (ii) mSLQQ-QOL, total FSFI and sexual desire, subjective arousal, lubrication, orgasm and satisfaction FSFI domains in untreated women partners.	Vardenafil Dihydrochloride	40-50	septin 3	Homo sapiens	138-142
16422810-6	2005	RESULTS: Compared with placebo, vardenafil significantly improved mean SEP2 and SEP3 success rates over the 12-week study period (intention-to-treat [ITT] and last observation carried forward [LOCF]) analysis).	Vardenafil Dihydrochloride	32-42	septin 3	Homo sapiens	80-84
16011816-10	2005	CONCLUSION: In this retrospective analysis of two pivotal trials, vardenafil improved success rates compared with placebo in ED patients who attempted intercourse from as early as 15 minutes or less and through 4-8 hours after dosing in ability to penetrate (SEP2) and from as early as 15 minutes or less and through 8-12 hours after dosing in maintenance of erection (SEP3).	Vardenafil Dihydrochloride	66-76	septin 3	Homo sapiens	369-373
15107017-0	2004	Phosphorylation of septin 3 on Ser-91 by cGMP-dependent protein kinase-I in nerve terminals.	Serine	31-34	septin 3	Homo sapiens	19-27
16422874-8	2005	Sexual intercourse was successfully completed (SEP3) in 69% and 84% of patients taking on-demand tadalafil and daily tadalafil, respectively, compared with 30% at baseline (P < 0.001).	Tadalafil	97-106	septin 3	Homo sapiens	47-51
16422874-8	2005	Sexual intercourse was successfully completed (SEP3) in 69% and 84% of patients taking on-demand tadalafil and daily tadalafil, respectively, compared with 30% at baseline (P < 0.001).	Tadalafil	117-126	septin 3	Homo sapiens	47-51
16739369-4	2005	The effectiveness of vardenafil was analysed on the basis of the parameters Sexual Encounter Profile (SEP) 2 (vaginal penetration) and SEP3 (erection maintenance) as also the "erectile function score" and overall satisfaction.	Vardenafil Dihydrochloride	21-31	septin 3	Homo sapiens	135-139
16422960-8	2004	For all classifications and for mild-to-moderate to severe ED, men treated with 10 or 20 mg of vardenafil showed statistically and clinically significant improvements (P < 0.001) in IIEF-EF scores, diary response rates to the SEP-2 and SEP-3 questions, and GAQ as compared with those given placebo.	Vardenafil Dihydrochloride	95-105	septin 3	Homo sapiens	239-244
15866997-8	2005	Men taking either 10- or 20-mg tadalafil had a significant increase in SEP3 from baseline scores vs placebo at both 24 hours (P = .038 and <.001 for 10 and 20 mg, respectively) and 36 hours (P < .001 for both doses) postdose.	Tadalafil	31-40	septin 3	Homo sapiens	71-75
15107017-3	2004	There are two motifs for potential PKG-I phosphorylation in Sept3, Thr-55 and Ser-91, but phosphoamino acid analysis revealed that the primary site is a serine.	Serine	153-159	septin 3	Homo sapiens	60-65
15107017-7	2004	Mutation of Ser-91 to Ala in recombinant Sept3 also abolished PKG phosphorylation, confirming that Ser-91 is the major site in vitro.	Serine	12-15	septin 3	Homo sapiens	41-46
15107017-8	2004	Antibodies raised against a peptide containing phospho-Ser-91 detected phospho-Sept3 only in the cytosol of nerve terminals, whereas Sept3 was located in a peripheral membrane extract.	Serine	55-58	septin 3	Homo sapiens	79-84
15107017-9	2004	Therefore Sept3 is phosphorylated on Ser-91 in nerve terminals and its phosphorylation may contribute to the regulation of its subcellular localization in neurons.	Serine	37-40	septin 3	Homo sapiens	10-15
15200239-2	2004	Human septin 3 was originally cloned during a screening of genes expressed in human teratocarcinoma cells induced to differentiate with retinoic acid.	Tretinoin	136-149	septin 3	Homo sapiens	6-14
15200239-4	2004	The purpose of the present study was to identify the expression patterns of human septin 3 isoforms in normal human brain and a human neuroblastoma cell line, SH-SY5Y, after retinoic acid-induced differentiation.	Tretinoin	174-187	septin 3	Homo sapiens	82-90
15082207-9	2004	Vardenafil improved successful SEP3 rates ranging from 58% to 74% compared to 22-34% for placebo.	Vardenafil Dihydrochloride	0-10	septin 3	Homo sapiens	31-35
33987996-8	2022	SEP2 and SEP3 were increased in both mirodenafil groups; however, the increase was not statistically significant for SEP2.	mirodenafil	37-48	septin 3	Homo sapiens	9-13
32431830-5	2020	In the present work, a complete compendium of crystal structures for the GTP-binding domains of all of the SEPT3 subgroup members when bound to either GDP or to a GTP analogue is provided.	Guanosine Triphosphate	73-76	septin 3	Homo sapiens	107-112
32431830-5	2020	In the present work, a complete compendium of crystal structures for the GTP-binding domains of all of the SEPT3 subgroup members when bound to either GDP or to a GTP analogue is provided.	Guanosine Diphosphate	151-154	septin 3	Homo sapiens	107-112
32431830-5	2020	In the present work, a complete compendium of crystal structures for the GTP-binding domains of all of the SEPT3 subgroup members when bound to either GDP or to a GTP analogue is provided.	Guanosine Triphosphate	163-166	septin 3	Homo sapiens	107-112
32431830-9	2020	Together, these results suggest a mechanism which couples GTP binding and hydrolysis to membrane association and implies a unique role for the SEPT3 subgroup in this process.	Guanosine Triphosphate	58-61	septin 3	Homo sapiens	143-148
31307951-10	2019	The analysis found that tadalafil daily had a greater improvement than tadalafil on-demand in terms of International Index of Erectile Function-Erectile Function (mean difference (MD) 1.24; 95% CI 0.03-2.44; P = .04), SEP2 (MD 10.08; 95% CI 9.15-11.01; P < .00001) and SEP3 (MD 8.19; 95% CI 2.09-14.29; P = .009) in treating ED after at least 24 weeks treatment cycle.	Tadalafil	24-33	septin 3	Homo sapiens	272-276
31699953-10	2019	This study showed that subjects who received tadalafil OAD had statistically significant higher increases of mean IIEF-EF (6.5 (SD 4.5) vs 4.9 (SD 4.2), p=0.032), proportion of "yes" responses to SEP-2 (81.8% vs 64.7%, p=0.025), and proportion of "yes" responses to SEP-3 (77.3% vs 60.3%, p=0.034).	Tadalafil	45-54	septin 3	Homo sapiens	266-271